Last reviewed · How we verify
Pravachol®
At a glance
| Generic name | Pravachol® |
|---|---|
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia
- Pravastatin for Prevention of Preeclampsia (PHASE1)
- Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions (PHASE1)
- Pravastatin Sodium 80 mg Tablets Under Fasting Conditions (PHASE1)
- Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects (PHASE1)
- Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects (PHASE1)
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (PHASE3)
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pravachol® CI brief — competitive landscape report
- Pravachol® updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI